Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 5Neoplasms 3Colorectal Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × brivanib × Clear all
NCT00355238 2023-12-01

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Bristol-Myers Squibb

Phase 2 Completed
137 enrolled 20 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00908752 2019-12-02

BRISK TA

Bristol-Myers Squibb

Phase 3 Completed
734 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01540461 2014-07-08

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Bristol-Myers Squibb

Phase 1 Completed
17 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00437424 2011-05-04

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡